Day: April 24, 2024

Second quarter 2023-2024 sales: down 1.8% Varying sales performance across activitiesQ2 sales(January 2024–March 2024)   2022-2023 2023-2024 Change (reported) Change (LFL*)Reported Reported €m % €m %             AGRICULTURAL SPRAYING   147.7 157.4 +9.7 +6.5% +12.0 +8.1%SUGAR BEET HARVESTERS   34.3 17.1 -17.2 -50.1% -17.1 -49.9%LEISURE     48.4 47.4 -1.0 -2.0% -4.4 -9.0%INDUSTRY     67.6 70.7 +3.1 +4.7% +3.3 +4.9%             EXEL Industries Group 297.9 292.6 -5.3 -1.8% -6.2 -2.1%6-monthsales(October 2023–March 2024)   2022-2023 2023-2024 Change (reported) Change (LFL*)Reported Reported €m % €m %             AGRICULTURAL...

Regulated information Intermediate declaration by the Board of Directors Ieper, Belgium – April 24th, 2024, 07.00 hrs CETDear, Please find herewith the link to our most recent press release: www.melexis.com/en/news/2024/financial/melexis-q1-2024-resultsAttachmentPR_ENG_Melexis_Q1 2024

Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024. The Rare Impact Awards honor individuals, groups and organizations who are making exceptional strides to improve the lives of people living with rare diseases. Pharming will accept the award in recognition of the U.S. Food and Drug Administration (FDA) approval and commercialization of Joenja® (leniolisib), an oral, selective PI3Kδ inhibitor. Joenja® is the first and only...

PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.       Q1 2024   Q1 2023   % change  €m   €m   Actual CER1Growth platforms2 509.7 452.0 12.8% 16.2%New medicines3 45.5 14.3 n/a n/aSomatuline® 257.8 263.2 -2.0% -1.3%Other 9.5 12.4 -23.8% -20.5%Total Sales 822.4 741.9 10.9% 13.3%HighlightsTotal-sales growth of 13.3% at CER1, or 10.9% as reported, driven by the 16.2%1 increase in sales of the growth platforms2 and the increased contributions from new medicines, while Somatuline sales declined by only 1.3%1Regulatory approval and launch of Onivyde in the U.S. as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) Confirmation of financial guidance for 2024...

OSLO, Norway (24 April 2024) – TGS will release its Q1 2024 results at approximately 07:00 CEST on 8 May 2024. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at House of Oslo, Ruseløkkveien 34, Oslo, Norway. The presentation is open to the public and can be followed live online. Access and registration for online attendees are available by copying and pasting this link into your browser: https://channel.royalcast.com/landingpage/hegnarmedia/20240508_16/ The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. For more information, visit TGS.com (http://www.tgs.com) or contact: CFO Sven Børre LarsenE-mail: investor@tgs.com Company SummaryTGS provides scientific data and intelligence to companies active in the energy sector. In addition...

PRESS RELEASE – PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going concern basis. Mont-Saint-Guibert, Belgium, 24 April 2024, 7:00 am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases, today announces the postponing of the publication of its 2023 annual report, as well as the annual general meeting of its shareholders, so that the Enterprise Court...

La Hulpe, Belgium – 24 April 2024, 7:00 a.m. CET – Unifiedpost Group SA (Euronext Brussels: UPG) (“Unifiedpost”), a leader in cloud-based business process solutions, will present an overview of its mid-term strategy on Tuesday, 30 April 2024.The event will take place from 2:00pm to 4:00pm CET on Tuesday, 30 April 2024. The presenting team will be Hans Leybaert, CEO, Koen De Brabander, CFO, and some of the group’s business leaders. The agenda for the day is as follows:Introductions Key objectives Business update Strategic initiatives Financial review Closing remarks Q&AThe event will take place virtually and will be available to stream via a live webcast. To register your interest in the event, please click the link below to subscribe:https://onlinexperiences.com/Launch/QReg/ShowUUID=69A1FEE7-5AFC-4DC2-BD32-0ED753E88D51 Should...